Posted by Michael Wonder on 28 Mar 2023
Amicus Therapeutics announces European Commission approval for Pombiliti in patients with late-onset Pompe disease
27 March 2023 - CHMP opinion for miglustat, the oral enzyme stabiliser component of AT-GAA, on track for 2Q, 2023.
Amicus Therapeutics today announced that the European Commission has granted approval for Pombiliti (cipaglucosidase alfa), a long-term enzyme replacement therapy used in combination with miglustat for adults with late-onset Pompe disease.
